Changing the way we treat multiple myeloma based on biological markers in 2016

Paulo Lúcio, MD, PhD of Champalimaud Clinical Center, Lisbon, Portugal discusses how to diagnose and monitor multiple myeloma (MM) in 2016 at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. The International Myeloma Working Group has updated the published guidelines on the diagnostic criteria, the risk assessment procedures as well as the treatment response assessment in the last two years. This means that in the last few years, the way we are looking at myeloma has changed, according to Dr Lucio. The most important change is that we are not treating end organ failure patients anymore as those patients are now treated before they get to that stage. This is accomplished through the use of biomarkers that predict the progression of disease. He further explains that, in his talk, he focused on these biological markers.
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.”

Share this video